10th Translational Research Conference
Myelodysplastic Syndromes, Overlap MDS/MPN Disorders and Clonal Haematopoiesis
Chairs: Pierre Fenaux, Katharina Götze, Mikkael Sekeres

10th Translational Research Conference
Myelodysplastic Syndromes, Overlap MDS/MPN Disorders and Clonal Haematopoiesis
Our Chairs
Information
October 16-18, 2026 – Malahide (Dublin), Ireland
Chairs: Pierre Fenaux, Katharina Götze, Mikkael Sekeres
#ESHMDS2026
ABOUT THE CONFERENCE:
The ESH 10th Translational Research Conference on Myelodysplastic Syndromes, Overlap MDS/MPN Disorders and Clonal Haematopoiesis will present the latest updates in some of the basic mechanisms of disease in MDS, MDS/MPN, and precursor conditions, and demonstrate how they are translated into clinical practice. Standards for treatment, timing and sequencing of treatment, and the latest clinical trial data and future directions for therapy will be discussed, along with interventions for clonal hematopoiesis precursor conditions.
Attendees will have the opportunity to learn practical approaches to treating these complicated diseases in a relaxed environment, with ample time provided for patient- and research centered questions, and for networking to create future clinical and research collaborations.
This educational conference has been approved for 17 CME-CPD credit points by the European Board for Accreditation in Hematology (EBAH)!
MAIN SCIENTIFIC TOPICS:
• Myelodysplastic Syndromes and the march of clonal haematopoiesis
• The VEXAS nexus
• Not another session on myelodysplastic syndromes classification and risk!
• Special Genetic Populations
• Looking at myelodysplastic syndromes with a Crystal Ball
• Treating Lower-risk myelodysplastic syndromes
• Treating Higher-risk myelodysplastic syndromes
• Transplantation
• Academic clinical trials
THE PROGRAMME WILL INCLUDE:
• Plenary Sessions
• Panel Discussions
• Simultaneous Meet the Expert Sessions
• Poster Walks
• Brief Oral Communications
• Ample time for in-depth discussions and networking
LEARNING OBJECTIVES:
• Describe the basic mechanisms of disease in MDS, MDS/MPN, and precursor conditions.
• Demonstrate how the basic mechanisms of myeloid malignancies are translated into clinical practice.
• Describe the treatment approach for lower-risk MDS and MDS/MPN.
• Describe the treatment approach for higher-risk MDS and MDS/MPN.
This conference is a Face to Face meeting. No virtual attendance is scheduled.
Programme
Read the scientific programme!
Abstract submission
CALL FOR ABSTRACTS IS CLOSED
Abstracts are eligible to be selected for a brief oral communications or a poster presentation.
Guidelines for your abstract submission:
1. Your abstract should be structured (e.g. Objectives, Methods, Results, Conclusions)
2. Maximum number of words: 500
3. You abstract will be submitted to the peer review procedure.
We accept “encore” abstract.
Presentation of data at this conference will not jeopardize acceptance of the same at the following ASH congress.
Venue
The Grand Hotel Malahide
Grove Road, Malahide, K36XT65 Dublin, Ireland
HOW TO GET THERE:
• From Dublin International Airport: Direct bus #102 to Malahide - Travel time: 50 minutes
• From Dublin City Centre: Direct train (Dart) to Malahide - Departure from Tara Street - Travel time: 45 minutes
Accommodation
The Grand Hotel Malahide
Grove Road, Malahide, County Dublin, K36 XT65, Ireland
The code for preferential rate will be provided in the conference registration confirmation email.
Deadline to book your accommodation at a preferential conference rate: September, 3rd, 2026.
After this date, room availability and conference rates cannot be guaranteed.
Warning!
We have detected scam activity of a company trying to sell accommodation services to the speakers of our conferences. Apparently, they have been collecting information on the speakers from the lists that are made public on our websites.
Please make sure you book your accommodation either via the link(s) provided by ESH on this page, or directly with the hotel or renown booking services platform.
Corporate partners
With the support of*:

Level 2 Conference Partner
*******

Supporting Conference Partner
*******
*ESH conference programmes are developed in strict scientific independence
with no input from corporate sponsors.


